Program Guide 2011 - American College of Allergy, Asthma and ...
Program Guide 2011 - American College of Allergy, Asthma and ...
Program Guide 2011 - American College of Allergy, Asthma and ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Saturday General SessionsEAACI Symposium • Room 210 • Hynes Convention CenterEndotypes <strong>and</strong> Phenotypes <strong>of</strong> Allergic DiseaseModerators: Cezmi A. Akdis, MD <strong>and</strong> Sami L. Bahna, MD, DrPH, FACAAI11:00 am Endotypes <strong>of</strong> <strong>Asthma</strong>Jan Lotvall, MD1256NoonPhenotypes <strong>of</strong> Food <strong>Allergy</strong>Antonella Muraro, MD12311:30 am How Infections Affect Different<strong>Asthma</strong> PhenotypesNikolaos Papadopoulos, MD123512:30 pm AdjournUpon completion <strong>of</strong> this session, participants should be able to: 1) identify clear asthma endotypes <strong>and</strong> comorbid processes thatmay influence asthma outcomes; 2) recognize differences between asthma phenotypes; 3) discuss the mechanisms <strong>of</strong> virusinducedasthma; <strong>and</strong> 4) describe the interactions between infections <strong>and</strong> allergic asthma.12:30 – 1:30 pmVisit ExhibitsLunch On Own(Concession St<strong>and</strong> Open in Exhibit Hall)12:30 – 1:30 pmPoster Session in Hall A(1st Floor)Plenary Session • Auditorium (2nd Floor) • Hynes Convention CenterThe Great Chronic Idiopathic Urticaria Raft Debate:After Antihistamines, What’s Best for Next In-Line TreatmentModerators: William K. Dolen, MD, FACAAI <strong>and</strong> David R. Weldon, MD, FACAAI1:30 pm OmalizumabRichard W. Weber, MD, FACAAICyclosporineDavid M. Lang, MD, FACAAI123Chronic CorticosteroidsJonathan A. Bernstein, MD, FACAAI123456Hydroxychloroquine/dapsoneDavid A. Khan, MD, FACAAI12MontelukastSheldon L. Spector, MD, FACAAI1234563:00 pm AdjournUpon completion <strong>of</strong> this session, participants should be able to: 1) discuss role <strong>of</strong> therapeutic modalities in urticaria beyond theroutine; 2) discuss rationale <strong>and</strong> success <strong>of</strong> omalizumab in treatment; 3) discuss treatment options for refractory hives; 4) describethe utility <strong>of</strong> using oral corticosteroids for the management <strong>of</strong> hives; 5) properly communicate the risks <strong>and</strong> benefits <strong>of</strong> using oralcorticosteroids for the treatment <strong>of</strong> hives; 6) explain the pathogenesis <strong>of</strong> urticaria; 7) discuss the effectiveness <strong>of</strong> antileukotrienesin the physical urticaria; 8) discuss the effectiveness <strong>of</strong> antileukotrienes in idiopathic chronic urticaria; 9) discuss the evidenceassociated with therapeutic options for patients with antihistamine-resistant urticaria/angioedema; 10) describe the utility <strong>of</strong>cyclosporine for patients with refractory chronic urticaria/angioedema; 11) discuss the role <strong>of</strong> dapsone in the management <strong>of</strong>refractory CIU; <strong>and</strong> 12) discuss the role <strong>of</strong> hydroxychloroquine in the management <strong>of</strong> refractory CIU.3:00 – 3:30 pm Refreshment Break in Exhibit Hall42Return to Table <strong>of</strong> Contents
Change language